太龙药业终止第四期员工持股计划并注销回购股份，拟减少注册资本

要点摘要

• 终止实施第四期员工持股计划：河南太龙药业股份有限公司（600222，以下简称“公司”）决定终止原计划的第四期员工持股计划。
• 回购股份用途变更并注销：公司拟将2022年8月3日至2023年7月13日期间回购的14,523,100股股份（占总股本2.53%）由“用于员工持股计划或股权激励”变更为“用于注销并减少公司注册资本”。
• 股本结构调整：注销完成后，公司总股本将从573,886,283股减少至559,363,183股，注册资本同步减少。
• 此事项需股东大会审议通过：相关议案已于2026年4月30日董事会及薪酬与考核委员会会议审议通过，尚需提交股东大会表决。
• 对公司影响：本次注销回购股份有助于提高每股收益和股东回报，不影响公司持续经营、债务履行能力和上市地位。

详细内容

1. 回购股份及员工持股计划回顾

2022年，公司董事会批准以不超过人民币7元/股的价格，通过集中竞价回购公司股份，用于员工持股计划或股权激励，回购资金总额区间为4,000万元至8,000万元。至2023年7月13日，公司累计回购股份14,523,100股，约占公司总股本的2.53%，回购均价为5.49元/股，合计使用资金79,724,005.75元。

2023年10月起，公司陆续召开相关会议并于11月2日获得临时股东大会批准，正式启动第四期员工持股计划。该计划原定股票来源为上述回购股份，员工以5.49元/股的价格认购，最高涉及14,523,100股。然而，截至公告披露日，相关股份尚未进行非交易过户，员工未签约、未缴款，计划并未实际落地。

2. 决定终止计划及原因

公司表示，鉴于市场融资环境、方案实施期限等多因素，充分征求员工意见后，为维护公司及股东利益，决定终止第四期员工持股计划。与之配套的管理办法等文件一并终止。

同时，为提升投资者回报、展现公司对自身长期价值的信心，公司拟将上述回购股份用途由“员工持股/股权激励”变更为“注销并减少注册资本”，并完成注销流程。

3. 股本结构变化

4. 对股东及公司影响

• 注销股份将直接减少流通股本，有望提升每股收益（EPS），对二级市场股价构成正面影响。
• 本次注销不会影响公司债务履行能力、持续经营能力，也不影响公司上市地位和股权分布。
• 不存在损害公司及中小股东利益的情形。

5. 审议及后续安排

该事项已获董事会审议通过（关联董事回避表决），尚需提交股东大会审议通过。公司将依法办理注销股份及工商变更等后续事项。

投资者需关注事项

• 本次股份注销将直接减少公司总股本，理论上利好每股收益指标，可能对公司股价产生积极影响。
• 公司主动终止员工持股计划，反映出在当前市场环境下对激励计划的谨慎态度，建议投资者关注公司后续激励及资本运作动向。
• 该议案尚需股东大会表决，建议股东密切关注公司公告及股东大会进展。

免责声明

本文仅基于公司公告内容整理，旨在为投资者提供资讯参考，不构成任何投资建议。投资有风险，入市需谨慎。

Taiji Pharmaceutical Terminates Fourth Employee Shareholding Plan and Will Cancel Repurchased Shares, Proposes to Reduce Registered Capital

Key Points

• Termination of the Fourth Employee Shareholding Plan: Henan Tailong Pharmaceutical Co., Ltd. (600222, “the Company”) has decided to terminate its planned fourth employee shareholding plan.
• Change of Use and Cancellation of Repurchased Shares: The Company proposes to change the use of 14,523,100 shares repurchased between August 3, 2022, and July 13, 2023 (accounting for 2.53% of total share capital), from “employee shareholding plan or equity incentive” to “cancellation and capital reduction.”
• Capital Structure Adjustment: After cancellation, the total share capital will reduce from 573,886,283 shares to 559,363,183 shares, with a corresponding decrease in registered capital.
• Subject to Shareholder Approval: The proposal has been approved at the board and remuneration committee meetings on April 30, 2026, and is pending approval at the shareholders’ meeting.
• Impact on the Company: Cancelling the repurchased shares will improve earnings per share and shareholder returns, without affecting the company’s solvency, business continuity, or listing status.

Details

1. Repurchased Shares and Employee Shareholding Plan Recap

In 2022, the board approved a share repurchase at a price not exceeding RMB 7 per share, with a funding range of RMB 40 million to RMB 80 million, for use in the employee shareholding plan or equity incentive. By July 13, 2023, a total of 14,523,100 shares (2.53% of total share capital) were repurchased at an average price of RMB 5.49 per share, costing RMB 79,724,005.75 in total.

From October to November 2023, the company convened relevant meetings and obtained shareholder approval to launch the fourth employee shareholding plan, which planned to use these repurchased shares at RMB 5.49 per share for employees. However, as of the announcement date, no shares had been transferred, nor had employees signed agreements or paid, meaning the plan had not been implemented.

2. Reasons for Termination

The company cited market financing environment and plan implementation deadline as key factors, and after full consultation with employees, decided to terminate the fourth employee shareholding plan and related documents to protect the interests of the company and its shareholders.

To further enhance investor returns and reflect confidence in the company’s long-term value, the company will change the use of the repurchased shares to cancellation and capital reduction, and proceed with the cancellation process.

3. Share Capital Structure Change

4. Impact on Shareholders and the Company

• The cancellation will directly reduce the total shares outstanding and is expected to improve EPS, likely having a positive effect on the share price.
• This action will not impact the company’s solvency, business continuity, listing status, or shareholding distribution.
• No harm to the interests of the company or minority shareholders is anticipated.

5. Approval and Next Steps

The proposal has been approved by the board (with related directors abstaining) and awaits shareholder approval. The company will proceed with share cancellation and relevant business registration changes as required.

Investor Alerts

• The share cancellation directly reduces share capital, which is theoretically positive for EPS and could boost the share price.
• The company’s cautious stance in terminating the employee incentive plan reflects its response to market conditions; investors should watch for future incentive or capital operations.
• The proposal must be approved at the shareholders’ meeting; investors are advised to monitor relevant announcements and meeting outcomes.

Disclaimer

This article is based solely on the company’s official announcement and is for informational purposes only. It does not constitute investment advice. Investing is risky. Please proceed with caution.

View 太龙药业 Historical chart here